

CLAIMS


1. Use of an effective amount of a compound selected from Formula (I), Formula (II), and Formula (III), or a pharmaceutically acceptable salt of the foregoing, in the preparation of a medicine for ameliorating or treating a viral infection caused by a virus selected from a henipavirus, a morbillivirus, a respirovirus, a rubulavirus and a metapneumovirus, wherein the compound is selected from Formula (I), Formula (II), and Formula (III) has one of the following structures:



(I)






(II)



(III)




wherein:




B^{1A} B^{1B} and B^{1C} are independently an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group;


R^{1A} is selected from the group consisting of hydrogen, an optionally substituted acyl, an optionally substituted O-linked amino acid, ,  and ;

when the dashed line (------) of Formula (I) is a single bond, R^{2A} is CH_2, and R^{3A} is O (oxygen);

when the dashed line (------) of Formula (I) is absent, R^{2A} is selected from the group consisting of an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted $-O-C_{1-6}$ alkyl, an optionally substituted $-O-C_{3-6}$ alkenyl, an optionally substituted $-O-C_{3-6}$ alkynyl and cyano, and R^{3A} is selected from the group consisting of OH, $-OC(=O)R''^{A}$ and an optionally substituted O-linked amino acid;

R^{1B} is selected from the group consisting of O^-, OH, , , , an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative;

R^{1C} and R^{2C} are independently selected from the group consisting of O^-, OH, an optionally substituted C_{1-6} alkoxy, , , , an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative; or

R^{1C} is  and R^{2C} is O^- or OH;






R^{2B} and R^{3C} are independently selected from the group consisting of an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted $-O-C_{1-6}$ alkyl, an optionally substituted $-O-C_{3-6}$ alkenyl, an optionally substituted $-O-C_{3-6}$ alkynyl and cyano;


R^{4C} is selected from the group consisting of OH, $-OC(=O)R^{"C}$ and an optionally substituted O-linked amino acid;

R^{4A}, R^{3B} and R^{5C} are independently a halogen;



R^{5A}, R^{4B} and R^{6C} are independently hydrogen or halogen;

R^{6A}, R^{7A} and R^{8A} are independently selected from the group consisting of absent, hydrogen, an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{3-6} cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted *–$(CR^{15A}R^{16A})_p$–O–C_{1-24} alkyl, an optionally substituted *–$(CR^{17A}R^{18A})_q$–O–C_{1-24} alkenyl,


,

,

,

and

; or



R^{6A} is and R^{7A} is absent or hydrogen; or

R^{6A} and R^{7A} are taken together to form a moiety selected from the group consisting of an optionally substituted  and an optionally substituted , wherein the oxygens connected to R^{6A} and R^{7A}, the phosphorus and the moiety form a six-membered to ten-membered ring system;.

R^{9A} is independently selected from the group consisting of an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{3-6} cycloalkenyl,

$NR^{30A}R^{31A}$, an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative;

R^{10A} and R^{11A} are independently an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative;

R^{12A}, R^{13A} and R^{14A} are independently absent or hydrogen;

each R^{15A}, each R^{16A}, each R^{17A} and each R^{18A} are independently hydrogen, an optionally substituted C_{1-24} alkyl or alkoxy;

R^{19A}, R^{20A}, R^{22A}, R^{23A}, R^{5B}, R^{6B}, R^{8B}, R^{9B}, R^{9C}, R^{10C}, R^{12C} and R^{13C} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl and an optionally substituted aryl;

R^{21A}, R^{24A}, R^{7B}, R^{10B}, R^{11C} and R^{14C} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl, an optionally substituted aryl, an optionally substituted –O–C_{1-24} alkyl and an optionally substituted –O–aryl;

R^{25A}, R^{29A}, R^{11B} and R^{15C} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl and an optionally substituted aryl;

R^{16C}, R^{17C} and R^{18C} are independently absent or hydrogen;

R^{26A} and R^{27A} are independently -C≡N or an optionally substituted substituent selected from the group consisting of C_{2-8} organylcarbonyl, C_{2-8} alkoxycarbonyl and C_{2-8} organylaminocarbonyl;

R^{28A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-24}-alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl and an optionally substituted C_{3-6} cycloalkenyl;

R^{30A} and R^{31A} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24}-alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl and an optionally substituted C_{3-6} cycloalkenyl;

for Formula (III), ------- is a single bond or a double bond;

when ------- is a single bond, each R^{7C} and each R^{8C} is independently hydrogen or halogen; and

when ------- is a double bond, each R^{7C} is absent and each R^{8C} is independently hydrogen or halogen;

$R^{"A}$ and $R^{"C}$ are independently an optionally substituted C_{1-24}-alkyl;


m and n are independently 0 or 1;

p and q are independently selected from the group consisting of 1, 2 and 3;

r is 1 or 2;

Z^{1A}, Z^{2A}, Z^{3A}, Z^{4A}, Z^{1B}, Z^{2B} and Z^{1C} are independently O or S; and

provided that when the dashed line (------) of Formula (I) is absent; R^{1A} is



wherein R^{8A} is an unsubstituted C_{1-4} alkyl or phenyl optionally para-substituted with a halogen or methyl and R^{9A} is methyl ester, ethyl ester, isopropyl ester, n-butyl ester, benzyl ester or phenyl ester of an amino acid selected from the group consisting of glycine, alanine, valine, leucine, phenylalanine, tryptophan, methionine and proline; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is fluoro or hydrogen; and B^{1A} is an unsubstituted uracil; then R^{2A} cannot be $-OCH_3$;

provided that when the dashed line (------) of Formula (I) is absent; R^{1A} is H; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is fluoro; and B^{1A} is an unsubstituted cytosine; then R^{2A} cannot be allenyl;

provided that when the dashed line (------) of Formula (I) is absent; R^{1A} is H; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is hydrogen; and B^{1A} is an unsubstituted thymine; then R^{2A} cannot be C_1 alkyl substituted with an N amido; and

provided that when the dashed line (------) of Formula (I) is absent; R^{1A} is H; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is fluoro; and B^{1A} is an unsubstituted cytosine; then R^{2A} cannot be ethynyl.

2. The use of Claim 1, wherein the virus is a henipavirus, a morbillivirus and/or a rubulavirus.

3. The use of Claim 2, wherein the henipavirus is a nipahvirus; wherein the morbillivirus is the measles virus; and/or wherein the rubulavirus is the mumps virus.

4. The use of Claim 1, wherein the virus is a respirovirus.

5. The use of Claim 4, wherein the respirovirus is human parainfluenza virus 1.

6. The use of Claim 4, wherein the respirovirus is human parainfluenza virus 3.



7. The use of Claim 1, wherein the virus is a rubulavirus.

8. The use of Claim 7, wherein the rubulavirus is human parainfluenza virus 2 and/or human parainfluenza virus 4.




9. The use of Claim 1, wherein the virus is a metapneumovirus.




10. The use of Claim 9, wherein the metaphenumovirus is human metapneumovirus.







11. The use of any one of Claims 1-10, wherein the compound is a compound of Formula (I).


12. The use of Claim 11, wherein R^{1A} is , or .


13. The use of Claim 12, wherein R^{6A} and R^{7A} are both hydrogen or absent.

14. The use of Claim 12, wherein one of R^{6A} and R^{7A} is hydrogen, and the other of R^{6A} and R^{7A} is selected from the group consisting of an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{3-6} cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted aryl(C_{1-6} alkyl); wherein both R^{6A} and R^{7A} are independently selected from the group consisting of an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{3-6} cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted aryl(C_{1-6} alkyl); wherein at least one of R^{6A} and R^{7A} are selected from the group consisting of , , and ; and the other of R^{6A} and R^{7A} is selected from the group consisting of absent, hydrogen, an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{3-6} cycloalkenyl, an optionally substituted aryl, an











optionally substituted heteroaryl and an optionally substituted aryl(C_{1-6} alkyl); wherein both R^{6A} and R^{7A} are independently selected from the group consisting of ,  and ; wherein R^{6A} and R^{7A} are both an optionally substituted C_{1-24} alkyl; wherein R^{6A} and R^{7A} are both an optionally substituted C_{2-24} alkenyl; wherein R^{6A} and R^{7A} are both *–$(CR^{15A}R^{16A})_p$–O–C_{1-24} alkyl; wherein R^{6A} and R^{7A} are both *–$(CR^{17A}R^{18A})_q$–O–C_{2-24} alkenyl; wherein R^{6A} and R^{7A} are both an optionally substituted aryl; or wherein R^{6A} and R^{7A} are both an optionally substituted aryl(C_{1-6} alkyl).





15. The use of Claim 12, wherein R^{6A} and R^{7A} are both ; wherein R^{6A} and R^{7A} are both ; wherein R^{6A} and R^{7A} are both ; wherein R^{6A} and R^{7A} are both ; wherein R^{6A} and R^{7A} are both ; or wherein R^{6A} and R^{7A} can be taken together to form a moiety selected from the group consisting of an optionally substituted  and an optionally

substituted , wherein the oxygens connected to R^{6A} and R^{7A}, the phosphorus and the moiety form a six-membered to ten-membered ring system.



16. The use of Claim 15, wherein is selected from the group consisting of:

, , , , , , , , , and or wherein R^{6A} and R^{7A} can be taken together to form a moiety selected from the group consisting of ,



,

,

and

,

wherein R^{32A} is an optionally substituted aryl, an optionally substituted heteroaryl or an optionally substituted heterocyclyl.

17. The use of any one of Claims 12-16, wherein Z^{1A} is O.

18. The use of any one of Claims 12-16, wherein Z^{1A} is S.

19. The use of Claim 12, wherein R^{8A} is selected from the group consisting of absent, hydrogen, an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl and an optionally substituted C_{3-6} cycloalkenyl; and R^{9A} is independently selected from the group consisting of an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl and an optionally substituted C_{3-6} cycloalkenyl; wherein R^{8A} is hydrogen, and R^{9A} is $NR^{30A}R^{31A}$, wherein R^{30} and R^{31} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl and an optionally substituted C_{3-6} cycloalkenyl; wherein R^{8A} is absent or hydrogen; and R^{9A} is an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative; or wherein R^{8A} is an optionally substituted aryl; and R^{9A} is an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative.

20. The use of Claim 12, wherein R^{9A} is selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine and ester derivatives thereof; or wherein R^{9A} is selected from the group consisting of alanine isopropyl ester, alanine cyclohexyl ester, alanine neopentyl ester, valine isopropyl ester and leucine isopropyl ester; or wherein R^{9A} has the structure  wherein R^{33A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6}-alkyl, an optionally substituted C_{3-6}


cycloalkyl, an optionally substituted aryl, an optionally substituted aryl(C_{1-6} alkyl) and an optionally substituted haloalkyl; R^{34A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{35A} is hydrogen or an optionally substituted C_{1-4}-alkyl; or R^{34A} and R^{35A} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

21. The use of Claim 20, wherein R^{34A} is an optionally substituted C_{1-6}-alkyl; R^{35A} is hydrogen; and/or R^{33A} is an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-6} cycloalkyl or an optionally substituted benzyl.

22. The use of any one of Claims 12 or 19-21, wherein Z^{2A} is O.

23. The use of any one of Claims 12 or 19-21, wherein Z^{2A} is S.

24. The use of Claim 12, wherein R^{10A} and R^{11A} are both an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative; wherein R^{10A} and R^{11A} are independently selected from selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine and ester derivatives thereof; wherein R^{10A} and R^{11A} are independently selected from the group consisting of alanine isopropyl ester, alanine cyclohexyl ester, alanine neopentyl ester, valine isopropyl ester and leucine isopropyl ester; or wherein R^{10A} and R^{11A} are independently have the structure




wherein R^{36A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6}-alkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted aryl(C_{1-6} alkyl) and an optionally substituted haloalkyl; R^{37A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{38A} is hydrogen or an optionally substituted C_{1-4}-alkyl; or R^{37A} and R^{38A} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

25. The use of Claim 24, wherein R^{37A} is an optionally substituted C_{1-6}-alkyl; R^{38A} is hydrogen and/or R^{36A} is an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-6} cycloalkyl or an optionally substituted benzyl.

26. The use of any one of Claims 12 or 24-25, wherein Z^{3A} is O.

27. The use of any one of Claims 12 or 24-25, wherein Z^{3A} is S.

28. The use of Claim 12, wherein R^{6A} is  and R^{7A} is absent or hydrogen; wherein R^{12A}, R^{13A} and R^{14A} are independently absent or hydrogen.


29. The use of Claim 28, wherein m is 0, and R^{12A} and R^{13A} are independently absent or hydrogen; or wherein m is 1, and R^{12A}, R^{13A} and R^{14A} are independently absent or hydrogen.

30. The use of Claim 11, wherein R^{1A} is H.

31. The use of Claim 11, wherein R^{1A} is an optionally substituted acyl.


32. The use of Claim 31, wherein the optionally substituted acyl is $-C(=O)R^{39A}$, wherein R^{39A} is selected from the group consisting of an optionally substituted C_{1-12} alkyl, an optionally substituted C_{2-12} alkenyl, an optionally substituted C_{2-12} alkynyl, an optionally substituted C_{3-8} cycloalkyl, an optionally substituted C_{5-8} cycloalkenyl, an optionally substituted C_{6-10} aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heteroaryl(C_{1-6} alkyl) and an optionally substituted heterocyclyl(C_{1-6} alkyl).

33. The use of Claim 32, wherein R^{39A} is an unsubstituted C_{1-12} alkyl.

34. The use of Claim 11, wherein R^{1A} is an optionally substituted O-linked amino acid; or wherein R^{1A} is  , wherein R^{40A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{41A} is hydrogen or an optionally substituted C_{1-4}-alkyl; or R^{40A} and R^{41A} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

35. The use of Claim 34, wherein R^{40A} is an optionally substituted C_{1-6}-alkyl; and/or R^{41A} is hydrogen.

36. The use of any one of Claims 11-35, wherein B^{1A} is selected from the group consisting of:



wherein:

R^{A2} is selected from the group consisting of hydrogen, halogen and NHR^{J2}, wherein R^{J2} is selected from the group consisting of hydrogen, $-C(=O)R^{K2}$ and $-C(=O)OR^{L2}$;

R^{B2} is halogen or NHR^{W2}, wherein R^{W2} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{3-8} cycloalkyl, $-C(=O)R^{M2}$ and $-C(=O)OR^{N2}$;

R^{C2} is hydrogen or NHR^{O2}, wherein R^{O2} is selected from the group consisting of hydrogen, $-C(=O)R^{P2}$ and $-C(=O)OR^{Q2}$;

R^{D2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl and an optionally substituted C_{2-6} alkynyl;

R^{E2} is selected from the group consisting of hydrogen, hydroxy, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-8} cycloalkyl, $-C(=O)R^{R2}$ and $-C(=O)OR^{S2}$;




R^{F2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6}alkyl, an optionally substituted C_{2-6} alkenyl and an optionally substituted C_{2-6} alkynyl;



Y^2 and Y^3 are independently N or CR^{I2}, wherein R^{I2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6}-alkyl, an optionally substituted C_{2-6}-alkenyl and an optionally substituted C_{2-6}-alkynyl;


R^{G2} is an optionally substituted C_{1-6} alkyl;

R^{H2} is hydrogen or NHR^{T2}, wherein R^{T2} is independently selected from the group consisting of hydrogen, $-C(=O)R^{U2}$ and $-C(=O)OR^{V2}$; and

R^{K2}, R^{L2}, R^{M2}, R^{N2}, R^{P2}, R^{Q2} R^{R2}, $R^{S2,}$ R^{U2} and R^{V2} are independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkenyl, C_{6-10} aryl, heteroaryl, heteroalicyclyl, aryl(C_{1-6} alkyl), heteroaryl(C_{1-6} alkyl) and heteroalicyclyl(C_{1-6} alkyl).

37. The use of Claim 36, wherein B^{1A} is  ;  or .

38. The use of Claim 36, wherein B^{1A} is  .or 

39. The use of Claim 36, wherein B^{1A} is  .

40. The use of any one of Claims 11-39, wherein the dashed line (------) is absent, R^{2A} is selected from the group consisting of an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl, an optionally substituted –O–C_{1-6} alkyl, an optionally substituted –O–C_{3-6} alkenyl, an optionally substituted –O–C_{3-6} alkynyl and cyano, and R^{3A} is selected from the group consisting of OH, -OC(=O)$R^{"A}$ and an optionally substituted O-linked amino acid.

41. The use of Claim 40, wherein R^{2A} is an optionally substituted C_{1-6} alkyl.

42. The use of Claim 41, wherein R^{2A} is a halogen substituted C_{1-6} alkyl, a hydroxy substituted C_{1-6} alkyl, an alkoxy substituted C_{1-6} alkyl or a sulfenyl substituted C_{1-6} alkyl.


43. The use of Claim 41, wherein R^{2A} is a halogen substituted C_{1-6} alkyl.

44. The use of Claim 40, wherein R^{2A} is an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted –O–C_{1-6} alkyl, an optionally substituted –O–C_{3-6} alkenyl, an optionally substituted –O–C_{3-6} alkynyl or cyano.

45. The use of any one of Claims 11-44, wherein R^{3A} is OH.

46. The use of any one of Claims 11-44, wherein R^{3A} is –OC(=O)$R^{"A}$, wherein $R^{"A}$ is an optionally substituted C_{1-8} alkyl.

47. The use of any one of Claims 11-44, wherein R^{3A} is O-linked amino acid.

48. The use of Claim 47, wherein the O-linked amino acid is selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine; or wherein R^{3A} is , wherein R^{42A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{43A} is hydrogen or an optionally substituted C_{1-4}-alkyl; or R^{42A} and R^{43A} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

49. The use of Claim 48, wherein R^{42A} is an optionally substituted C_{1-6}-alkyl; and/or R^{43A} is hydrogen.

50. The use of any one of Claims 11-49, wherein R^{5A} is hydrogen.


51. The use of any one of Claims 11-49, wherein R^{5A} is halogen.











52. The use of any one of Claims 11-51, wherein R^{4A} is fluoro.

53. The use of any one of Claims 1-10, wherein the compound is a compound of Formula (II).

54. The use of any one of Claims 1-10, wherein the compound is a compound of Formula (III).








55. The use of Claim 11, wherein the compound of Formula (I) is selected from the group consisting of:







R1AO
B1A
O
HO
F












and

, or a pharmaceutically acceptable salt of the foregoing.


56. The use of Claim 11, wherein the compound of Formula (I) is selected from the group consisting of:











O
N
N
N
N
NH2
HO
O
HO
F
,

O
N
N
HO
O
F

O
N
N
N
N
NH2
HO
O
HO
F
,

NH2
N
HO
O
Cl
HO
F

O
NH2






NH2
N
O
HO
O
N
Cl
O
F
O













,














NH2
N
HO
O
O
HO
F


NH2

NH














O
N
N
N
N
NH2
HO
O
HO
F
,

N
N
HO
O
Cl
HO
F

NH2
N
N
N
HO
O
F
HO
F
,

O
NH
N
N
N
HO
O
Cl
HO
F







,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,





,


,


,

,

,

,

,

,

,

,

,

,

,

,



,

,

,

and

, or a pharmaceutically acceptable salt of the foregoing.


57. The use of Claim 11, wherein the compound of Formula (I) is selected from the group consisting of:










,

,

,

,








,








,

,

,

,

,

,

,

,


,

,

,

and

, or a pharmaceutically acceptable salt of the foregoing.

58. The use of Claim 11, wherein the compound of Formula (I) is



, or a pharmaceutically acceptable salt thereof.

59. The use of Claim 58, wherein the compound of Formula (I) is




, or a pharmaceutically acceptable salt thereof.

60. The use of Claim 58, wherein the compound of Formula (I) is






, or a pharmaceutically acceptable salt thereof.






61. The use of Claim 58, wherein the compound of Formula (I) is










, or a pharmaceutically acceptable salt thereof.

62. The use of Claim 53, wherein the compound of Formula (II) is  ,  ,  and , or a pharmaceutically acceptable salt thereof.


63. The use of Claim 54, wherein the compound of Formula (III) is selected from the group consisting of:

 ,  ,  ,  ,  ,



,

,

,

,

,

and

, or a pharmaceutically acceptable salt of the foregoing.

CLAIMS


1. Use of an effective amount of a compound selected from Formula (I), Formula (II), and Formula (III), or a pharmaceutically acceptable salt of the foregoing, in the preparation of a medicine for ameliorating or treating a viral infection caused by a virus selected from a henipavirus, a morbillivirus, a respirovirus, a rubulavirus and a metapneumovirus, wherein the compound is selected from Formula (I), Formula (II), and Formula (III) has one of the following structures:



(I)






(II)





(III)

wherein:

B^{1A} is elected from the group consisting of:


,
, 
, 
,


and 
;

wherein:

R^{A2} is selected from the group consisting of hydrogen, halogen and NHR^{J2}, wherein R^{J2} is hydrogen;

R^{B2} is halogen or NHR^{W2}, wherein R^{W2} is hydrogen;

R^{C2} is hydrogen or NHR^{O2}, wherein R^{O2} is hydrogen;

R^{D2} is selected from the group consisting of hydrogen, halogen and an unsubstituted C_{1-6} alkyl;

R^{E2} is selected from the group consisting of hydrogen, hydroxy and an unsubstituted C_{1-6} alkyl;

R^{F2} is selected from the group consisting of hydrogen, halogen, and an unsubstituted C_{1-6}alkyl;


Y^2 is N;


Y^3 is N or CR^{I2}, wherein R^{I2} is hydrogen;


R^{G2} is an unsubstituted C_{1-6} alkyl; and


R^{H2} is hydrogen or NHR^{T2}, wherein R^{T2} is hydrogen;


B^{1B} is selected from the group consisting of:




,


,


,


,


and


;

wherein:

R^{AB2} is selected from the group consisting of hydrogen, halogen and NHR^{JB2}, wherein R^{JB2} is hydrogen;

R^{BB2} is halogen or NHR^{WB2}, wherein R^{WB2} is hydrogen;

R^{CB2} is hydrogen or NHR^{OB2}, wherein R^{OB2} is hydrogen;

R^{DB2} is selected from the group consisting of hydrogen, halogen and an unsubstituted C_{1-6} alkyl;

R^{EB2} is selected from the group consisting of hydrogen, hydroxy and an unsubstituted C_{1-6} alkyl;

R^{FB2} is selected from the group consisting of hydrogen, halogen and an unsubstituted C_{1-6}alkyl;


Y^{2B} is N;


Y^{3B} is CR^{IB2}, wherein R^{IB2} is hydrogen;


R^{GB2} is an unsubstituted C_{1-6} alkyl; and


R^{HB2} is hydrogen or NHR^{TB2}, wherein R^{TB2} is hydrogen;


B^{1C} is selected from the group consisting of:




,


,


,


,


and


;

wherein:

R^{AC2} is selected from the group consisting of hydrogen, halogen and NHR^{JC2}, wherein R^{JC2} is hydrogen,;

R^{BC2} is halogen or NHR^{WC2}, wherein R^{WC2} is hydrogen;

R^{CC2} is hydrogen or NHR^{OC2}, wherein R^{OC2} is hydrogen;

R^{DC2} is selected from the group consisting of hydrogen, halogen and an unsubstituted C_{1-6} alkyl;

R^{EC2} is selected from the group consisting of hydrogen, hydroxy and an unsubstituted C_{1-6} alkyl;




R^{FC2} is selected from the group consisting of hydrogen, halogen and an unsubstituted C_{1-6} alkyl;

Y^{2C} is N;

Y^{3C} is CR^{IC2}, wherein R^{IC2} is hydrogen;

R^{GC2} is an unsubstituted C_{1-6} alkyl; and



R^{HC2} is hydrogen or NHR^{TC2}, wherein R^{TC2} is hydrogen;


R^{1A} is selected from the group consisting of hydrogen, an optionally substituted acyl, an optionally substituted O-linked α–amino acid,   and ;


the dashed line (------) of Formula (I) is absent;

R^{2A} is selected from the group consisting of an unsubstituted C_{1-6} alkyl, a halogen substituted C_{1-6} alkyl, a hydroxy substituted C_{1-6} alkyl, an alkoxy substituted C_{1-6} alkyl, a sulfenyl substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted –O–C_{1-6} alkyl and cyano;

R^{3A} is selected from the group consisting of OH, $-OC(=O)R^{"A}$ and an optionally substituted O-linked α-amino acid;

R^{1B} is selected from the group consisting of O^-, OH,  and ;

R^{1C} and R^{2C} are independently selected from the group consisting of O^-, OH, an optionally substituted C_{1-6} alkoxy, and ; or

R^{1C} is  and R^{2C} is O^- or OH;


R^{2B} and R^{3C} are independently an optionally substituted C_{1-6} alkyl;

R^{4C} is OH;


R^{4A}, R^{3B} and R^{5C} are independently a halogen;

R^{5A}, R^{4B} and R^{6C} are independently hydrogen or halogen;


R^{6A}, R^{7A} and R^{8A} are independently selected from the group consisting of absent, hydrogen, optionally substituted aryl, an optionally substituted heteroaryl,



and




; or




R^{6A} is and R^{7A} is absent or hydrogen; or

R^{6A} and R^{7A} are taken together to form a moiety selected from the group consisting of an optionally substituted



and an optionally substituted



, wherein the oxygens connected to R^{6A} and R^{7A}, the phosphorus and the moiety form a six-membered to ten-membered ring system;

R^{9A} is an optionally substituted N-linked α–amino acid or an optionally substituted N-linked α–amino acid ester derivative;

R^{10A} and R^{11A} are independently an optionally substituted N-linked α–amino acid or an optionally substituted N-linked α–amino acid ester derivative;

R^{12A}, R^{13A} and R^{14A} are independently absent or hydrogen;

R^{22A}, R^{23A}, R^{8B}, R^{9B}, R^{12C} and R^{13C} are independently hydrogen or an unsubstituted C_{1-4} alkyl;

R^{24A}, R^{10B} and R^{14C} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl and an optionally substituted –O–C_{1-24} alkyl;

R^{25A} and R^{11B} are independently hydrogen or an optionally substituted C_{1-24} alkyl;

R^{16C}, R^{17C} and R^{18C} are independently absent or hydrogen;

for Formula (III), ------- is a single bond or a double bond;

when ------- is a single bond, each R^{7C} and each R^{8C} is independently hydrogen or halogen; and


when ------- is a double bond, each R^{7C} is absent and each R^{8C} is independently hydrogen or halogen;

$R^{"A}$ and $R^{"C}$ are independently an optionally substituted C_{1-24}-alkyl;

m and n are independently 0 or 1;

Z^{1A}, Z^{2A} and Z^{3A}, are independently O or S

Z^{4A}, Z^{1B}, Z^{2B} and Z^{1C} are O; and



provided that when R^{1A} is wherein R^{8A} is phenyl optionally para-substituted with a halogen or methyl and R^{9A} is methyl ester, ethyl ester, isopropyl ester, n-butyl ester, benzyl ester or phenyl ester of an α–amino acid selected from the group consisting of glycine, alanine, valine, leucine, phenylalanine, tryptophan, methionine and proline; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is fluoro or hydrogen; and B^{1A} is an unsubstituted uracil; then R^{2A} cannot be $-OCH_3$;

provided that when R^{1A} is H; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is fluoro; and B^{1A} is an unsubstituted cytosine; then R^{2A} cannot be allenyl; and

provided that when R^{1A} is H; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is fluoro; and B^{1A} is an unsubstituted cytosine; then R^{2A} cannot be ethynyl; and

a heteroaryl is a 4 to 14 atoms monocyclic or multicyclic aromatic ring system that contains one or more heteroatoms selected from nitrogen, oxygen and sulfur; and

when a substituent is indicated as optionally substituted. the substituent may be substituted with one or more group(s) individually and independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, alkoxy, aryloxy, acyl, mercapto, alkylthio, arylthio, cyano, halogen, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, an amino, a mono-substituted amino group and a di-substituted amino group;

2. The use of Claim 1, wherein the virus is a henipavirus, a morbillivirus and/or a rubulavirus.

3. The use of Claim 2, wherein the henipavirus is a nipahvirus; wherein the morbillivirus is the measles virus; and/or wherein the rubulavirus is the mumps virus.

4. The use of Claim 1, wherein the virus is a respirovirus.

5. The use of Claim 4, wherein the respirovirus is human parainfluenza virus 1.

6. The use of Claim 4, wherein the respirovirus is human parainfluenza virus 3.



7. The use of Claim 1, wherein the virus is a rubulavirus.

8. The use of Claim 7, wherein the rubulavirus is human parainfluenza virus 2 and/or human parainfluenza virus 4.


9. The use of Claim 1, wherein the virus is a metapneumovirus.


10. The use of Claim 9, wherein the metaphenumovirus is human metapneumovirus.



11. The use of any one of Claims 1-10, wherein the compound is a compound of Formula (I).






12. The use of Claim 11, wherein R^{1A} is , or .

13. The use of Claim 12, wherein R^{6A} and R^{7A} are both hydrogen or absent.

14. The use of Claim 12, wherein both R^{6A} and R^{7A} are .

15. The use of Claim 12, wherein R^{6A} and R^{7A} are both ;.


16. The use of Claim 12, wherein R^{6A} and R^{7A} can be taken together to form a moiety selected from the group consisting of an optionally substituted  and an optionally substituted , wherein the oxygens connected to R^{6A} and R^{7A}, the phosphorus and the moiety form a six-membered to ten-membered ring system; or

wherein R^{6A} and R^{7A} can be taken together to form a moiety selected from the group consisting of , , ,  and , wherein R^{32A} is an optionally substituted aryl, an optionally substituted heteroaryl or an optionally substituted heterocyclyl.

17. The use of any one of Claims 12-16, wherein Z^{1A} is O.

18. The use of any one of Claims 12-16, wherein Z^{1A} is S.

19. The use of Claim 12, wherein R^{8A} is an optionally substituted aryl; and R^{9A} is an optionally substituted N-linked α–amino acid or an optionally substituted N-linked α–amino acid ester derivative.


20. The use of Claim 12, wherein R^{9A} is selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine and ester derivatives thereof; or wherein R^{9A} is selected from the group consisting of alanine isopropyl ester, alanine cyclohexyl ester, alanine neopentyl ester, valine isopropyl ester and leucine isopropyl ester; or wherein R^{9A} has the structure  wherein R^{33A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6}-alkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted aryl(C_{1-6} alkyl) and an optionally substituted haloalkyl; R^{34A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally

substituted aryl(C_{1-6} alkyl); and R^{35A} is hydrogen or an optionally substituted C_{1-4}-alkyl; or R^{34A} and R^{35A} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

21. The use of Claim 20, wherein R^{34A} is an optionally substituted C_{1-6}-alkyl; R^{35A} is hydrogen; and R^{33A} is an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-6} cycloalkyl or an optionally substituted benzyl.

22. The use of any one of Claims 12 or 19-21, wherein Z^{2A} is O.


23. The use of any one of Claims 12 or 19-21, wherein Z^{2A} is S.

24. The use of Claim 12, wherein R^{10A} and R^{11A} are both an optionally substituted N-linked α–amino acid or an optionally substituted N-linked α–amino acid ester derivative; or wherein R^{10A} and R^{11A} are independently selected from selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine and ester derivatives thereof; or wherein R^{10A} and R^{11A} are independently selected from the group consisting of alanine isopropyl ester, alanine cyclohexyl ester, alanine neopentyl ester, valine isopropyl ester and leucine isopropyl ester; or wherein R^{10A} and R^{11A} are independently have the structure  wherein R^{36A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6}-alkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted aryl(C_{1-6} alkyl) and an optionally substituted haloalkyl; R^{37A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{38A} is hydrogen or an optionally substituted C_{1-4}-alkyl; or R^{37A} and R^{38A} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

25. The use of Claim 24, wherein R^{37A} is an optionally substituted C_{1-6}-alkyl; R^{38A} is hydrogen; and R^{36A} is an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-6} cycloalkyl or an optionally substituted benzyl.

26. The use of any one of Claims 12 or 24-25, wherein Z^{3A} is O.

27. The use of any one of Claims 12 or 24-25, wherein Z^{3A} is S.

28. The use of Claim 12, wherein R^{6A} is , R^{7A} is absent or hydrogen; m is 0 or 1; and R^{12A}, R^{13A} and R^{14A} are independently absent or hydrogen.


29. The use of Claim 28, wherein m is 0, and R^{12A} and R^{13A} are independently absent or hydrogen; or wherein m is 1, and R^{12A}, R^{13A} and R^{14A} are independently absent or hydrogen.

30. The use of Claim 11, wherein R^{1A} is H.

31. The use of Claim 11, wherein R^{1A} is an optionally substituted acyl.







32. The use of Claim 31, wherein the optionally substituted acyl is $-C(=O)R^{39A}$, wherein R^{39A} is an optionally substituted C_{1-12} alkyl or an optionally substituted C_{2-12} alkenyl.




33. The use of Claim 32, wherein R^{39A} is an unsubstituted C_{1-12} alkyl.



34. The use of Claim 11, wherein R^{1A} is an optionally substituted O-linked α–amino acid; or wherein R^{1A} is , wherein R^{40A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{41A} is hydrogen or an optionally substituted C_{1-4}-alkyl; or R^{40A} and R^{41A} are taken together to form an optionally substituted C_{3-6} cycloalkyl.


35. The use of Claim 34, wherein R^{40A} is an optionally substituted C_{1-6}-alkyl; and R^{41A} is hydrogen.

36. The use of any one of Claims 11-35, wherein B^{1A} is selected from the group consisting of:


, 
, 
, 
and 
and 
.

37. The use of Claim 36, wherein B^{1A} is 
, 
or 
.

38. The use of Claim 36, wherein B^{1A} is 
.or 

39. The use of Claim 36, wherein B^{1A} is 
.

40. The use of any one of Claims 11-39, wherein R^{2A} is a halogen substituted C_{1-6} alkyl or a sulfenyl substituted C_{1-6} alkyl, and R^{3A} is selected from the group consisting of OH, -OC(=O)$R^{"A}$ and an optionally substituted O-linked α–amino acid.

41. The use of any one of Claims 11-39, wherein R^{2A} is an unsubstituted C_{1-6} alkyl.

42. The use of Claim 40, wherein R^{2A} is a halogen substituted C_{1-6} alkyl.


43. The use of one of Claims 11-39, wherein R^{2A} is an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted –O–C_{1-6} alkyl or cyano.

44. The use of any one of Claims 11-43, wherein R^{3A} is OH.

45. The use of any one of Claims 11-43, wherein R^{3A} is –OC(=O)$R^{"A}$, wherein $R^{"A}$ is an optionally substituted C_{1-8} alkyl.

46. The use of Claim 45, wherein $R^{"A}$ is an unsubstituted C_{1-8} alkyl.

47. The use of any one of Claims 11-43, wherein R^{3A} is O-linked α–amino acid.

48. The use of Claim 47, wherein the O-linked α–amino acid is selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine; or wherein R^{3A} is 

, wherein R^{42A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{43A} is hydrogen or an optionally substituted C_{1-4}-alkyl; or R^{42A} and R^{43A} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

49. The use of Claim 48, wherein R^{42A} is an optionally substituted C_{1-6}-alkyl; and R^{43A} is hydrogen.

50. The use of any one of Claims 11-49, wherein R^{5A} is hydrogen.


51. The use of any one of Claims 11-49, wherein R^{5A} is halogen.











52. The use of any one of Claims 11-51, wherein R^{4A} is fluoro.

53. The use of any one of Claims 1-10, wherein the compound is a compound of Formula (II).

54. The use of any one of Claims 1-10, wherein the compound is a compound of Formula (III).








55. The use of Claim 11, wherein the compound of Formula (I) is selected from the group consisting of:



















and

, or a pharmaceutically acceptable salt of the foregoing.


56. The use of Claim 11, wherein the compound of Formula (I) is selected from the group consisting of:







NH2
N
O
HO
O
Cl
O
O
F













,














NH2
N
HO
O
O
HO
F














NH2
N






NH2
N


HO
O
N
N
N
N
NH2
HO
F
,

HO
N
N
Cl
HO
F

NH2
N
N
N
HO
O
F
HO
F
,

O
N
NH
N
HO
O
Cl
HO
F








,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,

,

,

,










,

,

and

, or a pharmaceutically acceptable salt of the foregoing.


57. The use of Claim 11, wherein the compound of Formula (I) is selected from the group consisting of:



,

,

,

,

,

,


NH2
N
O
F
HO
O
P
NH
H3C


NH2
N
O
O
O
Cl
O
F
O
NH2
N
O
O
O
Cl
O
F
O
NH2
N
O
O
O
Cl
HO
F


,

,

,

,

,

,

,

,




,


and



, or a pharmaceutically acceptable salt of the foregoing.

58. The use of Claim 11, wherein the compound of Formula (I) is




, or a pharmaceutically acceptable salt thereof.

59. The use of Claim 58, wherein the compound of Formula (I) is




, or a pharmaceutically acceptable salt thereof.

60. The use of Claim 58, wherein the compound of Formula (I) is




, or a pharmaceutically acceptable salt thereof.

61. The use of Claim 58, wherein the compound of Formula (I) is




, or a pharmaceutically acceptable salt thereof.


62. The use of Claim 53, wherein the compound of Formula (II) is



,













,





and , or a pharmaceutically acceptable salt thereof.

63. The use of Claim 54, wherein the compound of Formula (III) is selected from the group consisting of:


,

,

,

,

,

,

,

,

,



,


and


, or a pharmaceutically acceptable salt of the foregoing.